Skip to main content

Phase 3 Readout

UTHR: Phase 3 Topline: A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepa

December 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
December 1, 2026
Company
UNITED THERAPEUTICS Corp (UTHR)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepa

UTHR overview →
Indication
Cardiovascular Diseases; Hypertension; Pulmonary Arterial Hypertension

Other upcoming events for UTHR

Phase 3 ReadoutPhase 3 Topline: Opiate-sparing Post-operative Pain Control in Septorhinoplasty: A Prospective Randomized, Double Bli
Phase 2 StartPhase 2 Start: Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelo